{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T15:56:12Z","timestamp":1789314972942,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Individuals diagnosed with and treated for type 1 diabetes (T1D) have increased risk of micro- and macrovascular disease and excess mortality. Improving cardiovascular (CV) risk factors in individuals with T1D is known to reduce diabetes- related CV complications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To examine time trends in CV risk factor levels and CV-protective treatment patterns. Additionally, examine incidence rates of diabetes-related CV complications in relation to exposure CV-protective treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analysed records from 41,630 individuals with T1D, registered anytime between 1996 and 2017 in a nationwide diabetes register. We obtained CV risk factor measurements (2010\u20132017), CV-protective drug profiles (1996\u20132017) and CV complication history (1977\u20132017) from additional nationwide health registers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From 2010 to 2017 there were decreasing levels of HbA<jats:sub>1c<\/jats:sub>, LDL-C, and blood pressure. Decreasing proportion of smokers, individuals with glycaemic dysregulation (HbA<jats:sub>1c<\/jats:sub>\u2009\u2265\u200958\u00a0mmol\/mol), dyslipidaemia (LDL-C\u2009&gt;\u20092.6\u00a0mmol\/l), and hypertension (\u2265\u2009140\/85\u00a0mmHg). Yet, one fifth of the T1D population by January 1st, 2017 was severely dysregulated (HbA<jats:sub>1c<\/jats:sub>\u2009&gt;\u200975\u00a0mmol\/mol). A slight increase in levels of BMI and urinary albumin creatinine ratio and a slight decrease in estimated glomerular filtration rate (eGFR) levels was observed. By January 1st, 2017, one fourth of the T1D population had an eGFR\u2009&lt;\u200960\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>. The proportion of the T1D population redeeming lipid-lowering drugs (LLDs) increased from 5% in 2000 to 30% in 2010 followed by a plateau and then a decline. The proportion of the T1D population redeeming antihypertensive drugs (AHDs) increased from 28% in 1996 to 42% in 2010 followed by a tendency to decline. Use of LLDs was associated with lower incidence of micro- and macrovascular complications, while use of AHDs had higher incidence of CVD and CKD, when compared to non-use and discontinued use, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Improvements were seen in CV risk factor control among individuals with T1D in Denmark between 2010 and 2017. However, there is clearly a gap between current clinical guidelines and clinical practice for CV risk management in T1D. Action is needed to push further improvements in CV risk control to reduce CVD and the related excess mortality.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-022-01692-5","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:33:15Z","timestamp":1669311195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Time trends of cardiovascular risk management in type 1 diabetes\u00a0-\u00a0nationwide analyses of real-life data"],"prefix":"10.1186","volume":"21","author":[{"given":"Hanan","family":"Amadid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Katrine Bjerring","family":"Clemmensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte","family":"Vistisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit Eika","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"issue":"12","key":"1692_CR1","doi-asserted-by":"publisher","first-page":"e658","DOI":"10.1016\/S2468-2667(19)30224-5","volume":"4","author":"Nordic Burden of Disease C","year":"2019","unstructured":"Nordic Burden of Disease C. Life expectancy and disease burden in the Nordic countries: results from the global burden of diseases, injuries, and risk factors study 2017. Lancet Public Health. 2019;4(12):e658\u201369.","journal-title":"Lancet Public Health"},{"issue":"1","key":"1692_CR2","doi-asserted-by":"publisher","first-page":"e001071","DOI":"10.1136\/bmjdrc-2019-001071","volume":"8","author":"B Carstensen","year":"2020","unstructured":"Carstensen B, Ronn PF, Jorgensen ME. Prevalence, incidence and mortality of type 1 and type 2 diabetes in Denmark 1996\u20132016. BMJ Open Diabetes Res Care. 2020;8(1):e001071.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"1692_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1056\/NEJMc1706292","volume":"377","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Gudbjornsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;377(3):300\u20131.","journal-title":"N Engl J Med"},{"issue":"10","key":"1692_CR4","doi-asserted-by":"publisher","first-page":"e1001321","DOI":"10.1371\/journal.pmed.1001321","volume":"9","author":"SJ Livingstone","year":"2012","unstructured":"Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J, Cleland S, Leese GP, McKnight J, Morris AD, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med. 2012;9(10):e1001321.","journal-title":"PLoS Med"},{"key":"1692_CR5","doi-asserted-by":"publisher","first-page":"j5019","DOI":"10.1136\/bmj.j5019","volume":"359","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C. Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study. BMJ. 2017;359:j5019.","journal-title":"BMJ"},{"issue":"24","key":"1692_CR6","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1161\/CIRCULATIONAHA.118.034986","volume":"138","author":"DA McAllister","year":"2018","unstructured":"McAllister DA, Read SH, Kerssens J, Livingstone S, McGurnaghan S, Jhund P, Petrie J, Sattar N, Fischbacher C, Kristensen SL, et al. Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus. Circulation. 2018;138(24):2774\u201386.","journal-title":"Circulation"},{"issue":"16","key":"1692_CR7","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.116.025961","volume":"135","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjornsdottir S. Range of risk factor levels: control, mortality, and cardiovascular outcomes in type 1 diabetes mellitus. Circulation. 2017;135(16):1522\u201331.","journal-title":"Circulation"},{"issue":"25","key":"1692_CR8","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"DM Nathan","year":"2005","unstructured":"Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, Diabetes C Complications Trial\/Epidemiology of Diabetes I, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643\u201353.","journal-title":"N Engl J Med"},{"issue":"9753","key":"1692_CR9","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Cholesterol Treatment Trialists C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"key":"1692_CR10","unstructured":"Database DD: National \u00e5rsrapport 2017\/2018. In.; 2018."},{"issue":"11","key":"1692_CR11","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","volume":"133","author":"D Vistisen","year":"2016","unstructured":"Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, Jorgensen ME. Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the steno type 1 risk engine. Circulation. 2016;133(11):1058\u201366.","journal-title":"Circulation"},{"issue":"10","key":"1692_CR12","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/j.1464-5491.2011.03342.x","volume":"28","author":"J Cederholm","year":"2011","unstructured":"Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjornsdottir S, Swedish National Diabetes R. A new model for 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med. 2011;28(10):1213\u201320.","journal-title":"Diabet Med."},{"issue":"4","key":"1692_CR13","first-page":"441","volume":"53","author":"CB Pedersen","year":"2006","unstructured":"Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish civil registration system. A cohort of eight million persons. Dan Med Bull. 2006;53(4):441\u20139.","journal-title":"Dan Med Bull"},{"issue":"7 Suppl","key":"1692_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","volume":"39","author":"HW Kildemoes","year":"2011","unstructured":"Kildemoes HW, Sorensen HT, Hallas J. The Danish National prescription registry. Scand J Public Health. 2011;39(7 Suppl):38\u201341.","journal-title":"Scand J Public Health"},{"key":"1692_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2147\/CLEP.S99518","volume":"8","author":"ME Jorgensen","year":"2016","unstructured":"Jorgensen ME, Kristensen JK, Reventlov Husted G, Cerqueira C, Rossing P. The Danish adult diabetes registry. Clin Epidemiol. 2016;8:429\u201334.","journal-title":"Clin Epidemiol"},{"issue":"7 Suppl","key":"1692_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","volume":"39","author":"E Lynge","year":"2011","unstructured":"Lynge E, Sandegaard JL, Rebolj M. The Danish National patient register. Scand J Public Health. 2011;39(7 Suppl):30\u20133.","journal-title":"Scand J Public Health"},{"issue":"7 Suppl","key":"1692_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/1403494810394718","volume":"39","author":"JS Andersen","year":"2011","unstructured":"Andersen JS, Olivarius Nde F, Krasnik A. The Danish National health service register. Scand J Public Health. 2011;39(7 Suppl):34\u20137.","journal-title":"Scand J Public Health"},{"key":"1692_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2147\/CLEP.S99507","volume":"8","author":"N Andersen","year":"2016","unstructured":"Andersen N, Hjortdal JO, Schielke KC, Bek T, Grauslund J, Laugesen CS, Lund-Andersen H, Cerqueira C, Andresen J. The Danish registry of diabetic retinopathy. Clin Epidemiol. 2016;8:613\u20139.","journal-title":"Clin Epidemiol"},{"key":"1692_CR19","doi-asserted-by":"publisher","unstructured":"Arendt, J. F. H., Hansen, A. T., Ladefoged, S. A., S\u00f8rensen, H. T., Pedersen, L., & Adelborg, K. (2020). Existing Data Sources in Clinical Epidemiology: Laboratory Information System Databases in Denmark. Clinical Epidemiology, 12, 469\u2014475. https:\/\/doi.org\/10.2147\/CLEP.S245060.","DOI":"10.2147\/CLEP.S245060"},{"issue":"1","key":"1692_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"key":"1692_CR21","unstructured":"National behandlingsvejledning type 1 diabetes. https:\/\/endocrinology.dk\/nbv\/diabetes-melitus\/type-1-diabetes-mellitus\/."},{"issue":"4","key":"1692_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.kint.2020.06.024","volume":"98","author":"IH de Boer","year":"2020","unstructured":"de Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, Liew A, Michos ED, Navaneethan SD, Olowu WA, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney Int. 2020;98(4):839\u201348.","journal-title":"Kidney Int"},{"key":"1692_CR23","unstructured":"Body Mass Index -BMI [https:\/\/www.euro.int\/en\/health-topics\/disease-prevention\/nutrition\/a-healthy-lifestyle\/body-mass-index-bmi]"},{"issue":"39","key":"1692_CR24","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1093\/eurheartj\/ehz687","volume":"40","author":"PJ Grant","year":"2019","unstructured":"Grant PJ, Cosentino F. The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: new features and the \u2018Ten Commandments\u2019 of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen. Eur Heart J. 2019;40(39):3215\u20137.","journal-title":"Eur Heart J"},{"issue":"8","key":"1692_CR25","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00125-019-4900-7","volume":"62","author":"C Mair","year":"2019","unstructured":"Mair C, Wulaningsih W, Jeyam A, McGurnaghan S, Blackbourn L, Kennon B, Leese G, Lindsay R, McCrimmon RJ, McKnight J, et al. Glycaemic control trends in people with type 1 diabetes in Scotland 2004\u20132016. Diabetologia. 2019;62(8):1375\u201384.","journal-title":"Diabetologia"},{"issue":"12","key":"1692_CR26","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1001\/archinte.161.12.1501","volume":"161","author":"K Miura","year":"2001","unstructured":"Miura K, Daviglus ML, Dyer AR, Liu K, Garside DB, Stamler J, Greenland P. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med. 2001;161(12):1501\u20138.","journal-title":"Arch Intern Med"},{"issue":"12","key":"1692_CR27","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jama.2020.14545","volume":"324","author":"P Muntner","year":"2020","unstructured":"Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, Colantonio LD. Trends in blood pressure control among US adults with hypertension, 1999\u20132000 to 2017\u20132018. JAMA. 2020;324(12):1190\u2013200.","journal-title":"JAMA"},{"issue":"23","key":"1692_CR28","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMsa2032271","volume":"384","author":"M Fang","year":"2021","unstructured":"Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in U.S. adults, 1999\u20132018. N Engl J Med. 2021;384(23):2219\u201328.","journal-title":"N Engl J Med"},{"issue":"6","key":"1692_CR29","doi-asserted-by":"publisher","first-page":"e0179546","DOI":"10.1371\/journal.pone.0179546","volume":"12","author":"ML Jensen","year":"2017","unstructured":"Jensen ML, Jorgensen ME, Hansen EH, Aagaard L, Carstensen B. Long-term patterns of adherence to medication therapy among patients with type 2 diabetes mellitus in Denmark: the importance of initiation. PLoS ONE. 2017;12(6):e0179546.","journal-title":"PLoS ONE"},{"issue":"9","key":"1692_CR30","doi-asserted-by":"publisher","first-page":"E1655","DOI":"10.1210\/jc.2014-1317","volume":"99","author":"SK Holt","year":"2014","unstructured":"Holt SK, Lopushnyan N, Hotaling J, Sarma AV, Dunn RL, Cleary PA, Braffett BH, Gatcomb P, Martin C, Herman WH, et al. Prevalence of low testosterone and predisposing risk factors in men with type 1 diabetes mellitus: findings from the DCCT\/EDIC. J Clin Endocrinol Metab. 2014;99(9):E1655-1660.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1692_CR31","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1016\/j.orcp.2013.03.007","volume":"8","author":"SA Price","year":"2014","unstructured":"Price SA, Gorelik A, Fourlanos S, Colman PG, Wentworth JM. Obesity is associated with retinopathy and macrovascular disease in type 1 diabetes. Obes Res Clin Pract. 2014;8(2):e178-182.","journal-title":"Obes Res Clin Pract"},{"issue":"4","key":"1692_CR32","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1464-5491.2010.02956.x","volume":"27","author":"B Conway","year":"2010","unstructured":"Conway B, Miller RG, Costacou T, Fried L, Kelsey S, Evans RW, Orchard TJ. Temporal patterns in overweight and obesity in Type 1 diabetes. Diabet Med. 2010;27(4):398\u2013404.","journal-title":"Diabet Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01692-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01692-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01692-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:38:45Z","timestamp":1669311525000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01692-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1692"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01692-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to Danish law, ethical approval and patient consent is not required for register studies. Access and use of the described register data are approved by the Danish Data Protection Agency and Danish Health Data Agency (j-No: SDC-2017-026 and FSEID-00003715).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MEJ, HA. DV and KKBC own shares in Novo Nordisk A\/S. MEJ has received research grants from Astra Zeneca, Sanofi Aventis, AMGEN, and Boehringer Ingelheim. FP reports having received research grants from AstraZeneca, Novo Nordisk and Novartis and lecture fees from Novartis, Eli Lilly, MSD, AstraZeneca, Sanofi, Novo Nordisk and Boehringer Ingelheim and having served as a consultant for Astra Zeneca, Bayer, Amgen, Novo Nordisk and MSD. KKBC is currently employed by Novo Nordisk A\/S. No other potential conflicts of interest relevant to this article were reported for the remaining authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}